Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

17 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Validity, reliability, and responsiveness of the EQ-5D in inflammatory bowel disease in Germany.
Stark RG, Reitmeir P, Leidl R, König HH. Stark RG, et al. Inflamm Bowel Dis. 2010 Jan;16(1):42-51. doi: 10.1002/ibd.20989. Inflamm Bowel Dis. 2010. PMID: 19475674
Costs of inflammatory bowel disease in Germany.
Stark R, König HH, Leidl R. Stark R, et al. Pharmacoeconomics. 2006;24(8):797-814. doi: 10.2165/00019053-200624080-00006. Pharmacoeconomics. 2006. PMID: 16898849
Apolipoprotein A-IV is an independent predictor of disease activity in patients with inflammatory bowel disease.
Broedl UC, Schachinger V, Lingenhel A, Lehrke M, Stark R, Seibold F, Göke B, Kronenberg F, Parhofer KG, Konrad-Zerna A. Broedl UC, et al. Inflamm Bowel Dis. 2007 Apr;13(4):391-7. doi: 10.1002/ibd.20078. Inflamm Bowel Dis. 2007. PMID: 17206692
Resistin is an inflammatory marker of inflammatory bowel disease in humans.
Konrad A, Lehrke M, Schachinger V, Seibold F, Stark R, Ochsenkühn T, Parhofer KG, Göke B, Broedl UC. Konrad A, et al. Eur J Gastroenterol Hepatol. 2007 Dec;19(12):1070-4. doi: 10.1097/MEG.0b013e3282f16251. Eur J Gastroenterol Hepatol. 2007. PMID: 17998831
CXCL16 is a surrogate marker of inflammatory bowel disease.
Lehrke M, Konrad A, Schachinger V, Tillack C, Seibold F, Stark R, Parhofer IG, Broedl UC. Lehrke M, et al. Scand J Gastroenterol. 2008 Mar;43(3):283-8. doi: 10.1080/00365520701679249. Scand J Gastroenterol. 2008. PMID: 18938659
Health care use and costs of adverse drug events emerging from outpatient treatment in Germany: a modelling approach.
Stark RG, John J, Leidl R. Stark RG, et al. BMC Health Serv Res. 2011 Jan 13;11:9. doi: 10.1186/1472-6963-11-9. BMC Health Serv Res. 2011. PMID: 21232111 Free PMC article.
Medical care of type 2 diabetes in German disease management programmes: a population-based evaluation.
Stark RG, Schunk MV, Meisinger C, Rathmann W, Leidl R, Holle R; KORA Study Group. Stark RG, et al. Diabetes Metab Res Rev. 2011 May;27(4):383-91. doi: 10.1002/dmrr.1186. Diabetes Metab Res Rev. 2011. PMID: 21308948
The performance of a value set for the EQ-5D based on experienced health states in patients with inflammatory bowel disease.
Leidl R, Reitmeir P, König HH, Stark R. Leidl R, et al. Value Health. 2012 Jan;15(1):151-7. doi: 10.1016/j.jval.2011.08.004. Epub 2011 Oct 7. Value Health. 2012. PMID: 22264983
Improving care of post-infarct patients: effects of disease management programmes and care according to international guidelines.
Stark R, Kirchberger I, Hunger M, Heier M, Leidl R, von Scheidt W, Meisinger C, Holle R. Stark R, et al. Clin Res Cardiol. 2014 Mar;103(3):237-45. doi: 10.1007/s00392-013-0643-5. Epub 2013 Nov 28. Clin Res Cardiol. 2014. PMID: 24287605
Towards patient-oriented diabetes care: results from two KORA surveys in southern Germany.
Schunk M, Stark R, Reitmeir P, Meisinger C, Holle R. Schunk M, et al. J Diabetes Res. 2015;2015:368570. doi: 10.1155/2015/368570. Epub 2015 Mar 17. J Diabetes Res. 2015. PMID: 25859544 Free PMC article.
17 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page
Feedback